Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells.

ABSTRACT: Plerixafor, a direct antagonist of CXCR4/stromal-derived factor 1, can safely and rapidly mobilize allografts without the use of granulocyte colony-stimulating factor (G-CSF). We conducted a phase 2, multicenter, prospective study of plerixafor-mobilized HLA-identical sibling allografts for allogeneic hematopoietic cell transplantation in recipients with hematological malignancies. Donors (n = 64) were treated with subcutaneous plerixafor (240 µg/kg) and started leukapheresis (LP) 4 hours later. The primary objective was to determine the proportion of donors who were successfully mobilized: defined as collection of ≥2.0 × 10⁶ CD34⁺ cells per kilogram recipient weight in ≤2 LP sessions. Recipients subsequently received reduced intensity (RIC; n = 33) or myeloablative (

SUBMITTER: Chen YB 

PROVIDER: S-EPMC6436017 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature